First Hospital, Tbilisi, is considered one of the best sites in Georgia by contract research organizations (CROs) running clinical trials due to the quantity of screened patients. The hospital serves the Tbilisi area (population: 1.2 M) and has 100 beds. It works in emergency medicine, critical care, general surgery, gynecology, traumatology, orthopedics, cardiology, anesthesiology, neurology, colon and rectal surgery, angiology, internal medicine, neurosurgery, transfusiology, and neonatology, with a specialization in intensive care, incl. for clinical trials. Becoming a partner in Clinerion’s global network of hospitals, First Hospital gains access to leading edge medical interventions for its patients and clinicians. International pharmaceutical companies use Clinerion’s real world data solutions to match in-development treatments with real patient populations along the entire drug development workflow, from trial protocol design optimization, to site feasibility assessment, to site selection, to the search and identification of patients eligible for enrolment in clinical trials. Clinerion’s network of partner hospitals expands significantly again with First Hospital. Clinerion’s clients – pharmaceutical companies and contract research organizations – now have the possibility to assess possible trial populations in Georgia for inclusion in their trials. “First Hospital has assembled a team of experienced, professional, motivated doctors. Some of the members of our team are internationally recognized, such as our Clinical Director Zaza Metreveli, who has been awarded a WHO prize for research in health promotion for his special contribution to medicine,” says David Oshkhereli, Director of First Hospital. I am very happy that Clinerion is now able to expand its services now into the Caucasus region,” says Ian Rentsch, CEO of Clinerion. “I am equally happy in the trust that First Hospital has placed in the benefits Clinerion can bring to its standing in the global community of hospital care. We will support each other as partners in the truest sense.” About Clinerion Clinerion enables early patient access to innovative treatments through real-patient data solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Network Explorer accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-driven protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website: www.clinerion.com Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/Clineriontechnologysolution For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.